A Phase 1/2 interventional study of Pemigatinib and Gemcitabine in Lung Cancer, Solid Tumor and Gastric Cancer, sponsored by Incyte Corporation. Terminated at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-06.
Sponsored by Incyte Corporation · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lung Neoplasms by Incyte Corporation — none open to participants now, 1 under way, none of them phase 3. Lung Neoplasms · Incyte Corporation.
Among the 11 studies in Lung Neoplasms by Incyte Corporation, this one is the 5th largest by enrollment, is one of 2 that started in 2015, is one of 5 in phase 1/2, and was the 4th registered.
5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →None of the 11 studies in Lung Neoplasms by Incyte Corporation is open now. The open studies under Lung Neoplasms, anywhere →
Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 1
First in 2014; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 60 across 3,657 interventional studies indexed under Lung Neoplasms.
Median enrollment 176 across the 11 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
1 of the studies in Lung Neoplasms by Incyte Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02955940Incyte CorporationAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Lung Neoplasms by Incyte Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(ECOG) performance status:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants self-administered oral pemigatinib 1/2/4 milligrams (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 7.5 mg twice daily (BID) on Days 1 through 21 of each 21-day cycle.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 10 mg BID on Days 1 through 21 of each 21-day cycle.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.
Drug: Pemigatinib
Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.
Drug: Pemigatinib
Participants received gemcitabine (Gem) intravenously starting at 1000 mg/meters squared (m\^2) (30 minutes) on Days 1 and 8 of each 21-day cycle. Cisplatin (Cis) was administered intravenously starting at 70 mg/m\^2 (1-4 hours) once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.
Drug: Pemigatinib · Drug: Gemcitabine · Drug: Cisplatin
Participants received gemcitabine intravenously starting at 1000 mg/m\^2 (30 minutes) on Days 1 and 8 of each 21-day cycle. Cisplatin was administered intravenously starting at 70 mg/m\^2 (1-4 hours) once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.
Drug: Pemigatinib · Drug: Gemcitabine · Drug: Cisplatin
Trastuzumab (Tras) was administered as an open-label, commercial product at an initial dose of 8 mg/kilograms (kg) over a 90-minute intravenous infusion, followed by 6 mg/kg over a 30- to 90-minute intravenous infusion once every 3 weeks. The dose could have been adjusted for toxicity management, per commercial labeling. The investigator could have interrupted, modified, or discontinued trastuzumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of trastuzumab.
Drug: Pemigatinib · Drug: Trastuzumab
Participants received docetaxel (Doc) intravenously starting at 75 mg/m\^2 (1 hour) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of docetaxel.
Drug: Pemigatinib · Drug: Docetaxel
Participants received pembrolizumab (Pem) intravenously at 200 mg (30 minutes) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.
Drug: Pemigatinib · Drug: Pembrolizumab
Participants received pembrolizumab intravenously at 200 mg (30 minutes) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.
Drug: Pemigatinib · Drug: Pembrolizumab
Participants received pembrolizumab intravenously at 200 mg (30 minutes) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.
Drug: Pemigatinib · Drug: Pembrolizumab
Retifanlimab (Ref) was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial dose of 500 mg over a 60-minute intravenous infusion. Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.
Drug: Pemigatinib · Drug: Retifanlimab
Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial dose of 500 mg over a 60-minute intravenous infusion. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.
Drug: Pemigatinib · Drug: Retifanlimab
Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial dose of 500 mg over a 60-minute intravenous infusion. Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.
Drug: Pemigatinib · Drug: Retifanlimab
Also known as: INCB054828
Also known as: INCMGA00012
Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.
Time frame: up to 763 days
Part 3: Number of Participants With Any TEAE
Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.
Time frame: up to 869 days
E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
E0 was defined as the Baseline serum concentration of phosphate.
Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
EC50 was defined as the pemigatinib steady-state area under the plasma or serum concentration-time curve that increases 50% of serum phosphate.
Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
Emax was defined as the maximum degree of increasing of serum phosphate by pemigatinib.
Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2
Serum phosphate concentration was assessed throughout Parts 1 and 2.
Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
Part 2: Overall Response Rate (ORR)
ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
Time frame: up to 126 days
Part 3: ORR
ORR was defined as the percentage of participants with a best overall response of CR or PR, per RECIST version 1.1, as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
Time frame: up to 203 days
Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1
Cmax was defined as the maximum observed plasma concentration.
Time frame: Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1
Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1
tmax was defined as the time to the maximum observed plasma concentration.
Time frame: Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1
Parts 1 and 2: AUClast After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1
AUClast was defined as the area under the plasma or serum concentration-time curve from the time of dosing to the last measurable concentration.
Time frame: Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1
Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1
AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.
Time frame: Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1
Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
Cmax was defined as the maximum observed plasma concentration.
Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
tmax was defined as the time to the maximum observed plasma concentration.
Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Parts 1 and 2: t1/2 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
t1/2 was defined as the apparent plasma terminal phase disposition half-life.
Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Parts 1 and 2: Cmin After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
Cmin was defined as the minimum observed plasma concentration over the dose interval.
Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.
Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Parts 1 and 2: CL/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
CL/F was defined as the apparent oral dose clearance.
Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Parts 1 and 2: Vz/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
Vz/F was defined as the apparent volume of distribution.
Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Parts 1 and 2: Accumulation Ratio After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
The accumulation ratio was defined as the ratio of the accumulation of a drug under steady-state conditions as compared to a single dose.
Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Parts 1 and 2: Cmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
Cmax was defined as the maximum observed plasma concentration.
Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Parts 1 and 2: Tmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
tmax was defined as the time to the maximum observed plasma concentration.
Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Parts 1 and 2: t1/2 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
t1/2 was defined as the apparent plasma terminal phase disposition half-life.
Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Parts 1 and 2: Cmin Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
Cmin was defined as the minimum observed plasma concentration over the dose interval.
Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Parts 1 and 2: AUC0-24 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.
Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Parts 1 and 2: CL/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
CL/F was defined as the apparent oral dose clearance.
Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Parts 1 and 2: Vz/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
Vz/F was defined as the apparent volume of distribution.
Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Part 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1
Cmax was defined as the maximum observed plasma concentration.
Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1
Part 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1
tmax was defined as the time to the maximum observed plasma concentration.
Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1
Part 3: AUClast of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1
AUClast was defined as the area under the plasma or serum concentration-time curve from the time of dosing to the last measurable concentration.
Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1
Part 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1
AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.
Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1
Part 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
Cmax was defined as the maximum observed plasma concentration.
Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Part 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
tmax was defined as the time to the maximum observed plasma concentration.
Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Part 3: t1/2 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
t1/2 was defined as the apparent plasma terminal phase disposition half-life.
Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Part 3: Cmin of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
Cmin was defined as the minimum observed plasma concentration over the dose interval.
Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Part 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.
Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Part 3: CL/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
CL/F was defined as the apparent oral dose clearance.
Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Part 3: Vz/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
Vz/F was defined as the apparent volume of distribution.
Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Part 3: Accumulation Ratio of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
The accumulation ratio was defined as the ratio of the accumulation of a drug under steady-state conditions as compared to a single dose.
Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
This study was conducted at 15 study sites: 14 sites in the United States and 1 site in Denmark. The study was conducted in 3 parts. Participants self-administered once daily doses of pemigatinib on a 2-weeks-on/1-week-off therapy (intermittent) or continuous schedule in 21-day cycles. Participants also self-administered twice daily doses of pemigatinib on a continuous schedule.
| Milestone | Part 1: Intermittent Pemigatinib 1/2/4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Part 1: Intermittent Pemigatinib 9 mg QD | Part 1: Intermittent Pemigatinib 13.5 mg QD | Part 1: Intermittent Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 9 mg QD | Part 1: Continuous Pemigatinib 13.5 mg QD | Part 1: Continuous Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 7.5 mg BID | Part 1: Continuous Pemigatinib 10 mg BID | Part 2: Intermittent Pemigatinib 9 mg QD | Part 2: Intermittent Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 9 mg QD | Part 2: Continuous Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 20 mg QD | Part 3: Gem/Cis/Intermittent Pemigatinib 9 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 9 mg | Part 3: Ref/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 20 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 4 | 3 | 6 | 6 | 9 | 10 | 9 | 4 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 4 | 3 | 6 | 6 | 9 | 9 | 8 | 4 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 2 | 3 | 6 | 6 | 6 | 5 | 8 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical decline; withdrew by physician | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Intermittent Pemigatinib 1/2/4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Part 1: Intermittent Pemigatinib 9 mg QD | Part 1: Intermittent Pemigatinib 13.5 mg QD | Part 1: Intermittent Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 9 mg QD | Part 1: Continuous Pemigatinib 13.5 mg QD | Part 1: Continuous Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 7.5 mg BID | Part 1: Continuous Pemigatinib 10 mg BID | Part 2: Intermittent Pemigatinib 9 mg QD | Part 2: Intermittent Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 9 mg QD | Part 2: Continuous Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 20 mg QD | Part 3: Gem/Cis/Intermittent Pemigatinib 9 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 9 mg | Part 3: Ref/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 20 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 44 | 5 | 20 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 44 | 5 | 20 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 1 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 29 | 4 | 15 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Intermittent Pemigatinib 1/2/4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Part 1: Intermittent Pemigatinib 9 mg QD | Part 1: Intermittent Pemigatinib 13.5 mg QD | Part 1: Intermittent Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 9 mg QD | Part 1: Continuous Pemigatinib 13.5 mg QD | Part 1: Continuous Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 7.5 mg BID | Part 1: Continuous Pemigatinib 10 mg BID | Part 2: Intermittent Pemigatinib 9 mg QD | Part 2: Intermittent Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 9 mg QD | Part 2: Continuous Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 20 mg QD | Part 3: Gem/Cis/Intermittent Pemigatinib 9 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 9 mg | Part 3: Ref/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 20 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 6 | 7 | 3 | 14 | 9 | 7 | 9 | 2 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 6 | 7 | 3 | 14 | 9 | 7 | 8 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 5 | 5 | 3 | 7 | 5 | 6 | 3 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 1 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Rolled over to another protocol after receiving same treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Placed on hospice; declined further follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.
| Participants | Part 1: Intermittent Pemigatinib 1/2/4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent Pemigatinib 13.5 mg QD | Part 1: Intermittent Pemigatinib 20 mg QD | Parts 1 and 2: Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Continuous Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 7.5 mg BID | Part 1: Continuous Pemigatinib 10 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 3 | 3 | 7 | 50 | 6 | 14 | 30 | 15 | 4 | 3 |
Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.
| Participants | Part 3: Gem/Cis/Intermittent Pemigatinib 9 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 9 mg | Part 3: Ref/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 20 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Part 3: Number of Participants With Any TEAE | 1 | 7 | 6 | 7 | 3 | 14 | 9 | 7 | 9 | 2 |
E0 was defined as the Baseline serum concentration of phosphate.
| milligrams per deciliter (mg/dL) | Parts 1 and 2: Intermittent or Continuous Pemigatinib |
|---|---|
| E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2 | 3.66 ± 1.91 |
EC50 was defined as the pemigatinib steady-state area under the plasma or serum concentration-time curve that increases 50% of serum phosphate.
| hours*nanomoles | Parts 1 and 2: Intermittent or Continuous Pemigatinib |
|---|---|
| EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2 | 1573 ± 21.6 |
Emax was defined as the maximum degree of increasing of serum phosphate by pemigatinib.
| mg/dL | Parts 1 and 2: Intermittent or Continuous Pemigatinib |
|---|---|
| Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2 | 5.76 ± 7.76 |
Serum phosphate concentration was assessed throughout Parts 1 and 2.
| mg/dL | Parts 1 and 2: Intermittent or Continuous Pemigatinib |
|---|---|
| Minimum value in range of highest values for all participants | 3.5 |
| Maximum value in range of highest values for all participants | 11.2 |
ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
| percentage of participants | Part 2: Intermittent Pemigatinib 9 mg QD | Part 2: Intermittent Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 9 mg QD | Part 2: Continuous Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 20 mg QD |
|---|---|---|---|---|---|
| Part 2: Overall Response Rate (ORR) | 25.0 (0.6 to 80.6) | 4.5 (0.6 to 15.5) | 0.0 (0.0 to 52.2) | 30.0 (11.9 to 54.3) | 0.0 (0.0 to 45.9) |
ORR was defined as the percentage of participants with a best overall response of CR or PR, per RECIST version 1.1, as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
| percentage of participants | Part 3: Gem/Cis/Intermittent Pemigatinib 9 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 9 mg | Part 3: Ref/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 20 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Part 3: ORR | 0.0 (0.0 to 97.5) | 42.9 (9.9 to 81.6) | 0.0 (0.0 to 45.9) | 14.3 (0.4 to 57.9) | 0.0 (0.0 to 70.8) | 28.6 (8.4 to 58.1) | 33.3 (7.5 to 70.1) | 0.0 (0.0 to 41.0) | 22.2 (2.8 to 60.0) | 0.0 (0.0 to 84.2) |
Cmax was defined as the maximum observed plasma concentration.
| nanograms per milliliter (ng/mL) | Part 1: Intermittent Pemigatinib 1 mg QD | Part 1: Intermittent Pemigatinib 2 mg QD | Part 1: Intermittent Pemigatinib 4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1 | 25.3 ± NA | 13.6 ± NA | 109 ± NA | 64.6 ± 9.16 | 139 ± 79.8 | 196 ± 121 | 300 ± 135 |
tmax was defined as the time to the maximum observed plasma concentration.
| hours (hr) | Part 1: Intermittent Pemigatinib 1 mg QD | Part 1: Intermittent Pemigatinib 2 mg QD | Part 1: Intermittent Pemigatinib 4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1 | 1 (NA to NA) | 5.92 (NA to NA) | 2.02 (NA to NA) | 1.14 (1.00 to 2.08) | 1.17 (0.500 to 2.13) | 1.20 (0.400 to 26.1) | 1.98 (0.500 to 22.9) |
AUClast was defined as the area under the plasma or serum concentration-time curve from the time of dosing to the last measurable concentration.
| hr*ng/mL | Part 1: Intermittent Pemigatinib 1 mg QD | Part 1: Intermittent Pemigatinib 2 mg QD | Part 1: Intermittent Pemigatinib 4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: AUClast After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1 | 190 ± NA | 68.8 ± NA | 1010 ± NA | 641 ± 116 | 1140 ± 498 | 1820 ± 1210 | 2510 ± 935 |
AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.
| hr*ng/mL | Part 1: Intermittent Pemigatinib 1 mg QD | Part 1: Intermittent Pemigatinib 2 mg QD | Part 1: Intermittent Pemigatinib 4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1 | 191 ± NA | NA ± NA | 1010 ± NA | 644 ± 115 | 1150 ± 497 | 1840 ± 1080 | 2850 ± 1050 |
Cmax was defined as the maximum observed plasma concentration.
| ng/mL | Part 1: Intermittent Pemigatinib 1 mg QD | Part 1: Intermittent Pemigatinib 2 mg QD | Part 1: Intermittent Pemigatinib 4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State) | 26.2 ± NA | 22.9 ± NA | 103 ± NA | 86.1 ± 38.0 | 196 ± 123 | 271 ± 151 | 449 ± 172 |
tmax was defined as the time to the maximum observed plasma concentration.
| hr | Part 1: Intermittent Pemigatinib 1 mg QD | Part 1: Intermittent Pemigatinib 2 mg QD | Part 1: Intermittent Pemigatinib 4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State) | 1.07 (NA to NA) | 3.98 (NA to NA) | 2.02 (NA to NA) | 1.58 (0.983 to 23.7) | 1.00 (0.500 to 6.10) | 1.13 (0.500 to 6.00) | 1.12 (0.517 to 5.90) |
t1/2 was defined as the apparent plasma terminal phase disposition half-life.
| hr | Part 1: Intermittent Pemigatinib 1 mg QD | Part 1: Intermittent Pemigatinib 2 mg QD | Part 1: Intermittent Pemigatinib 4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: t1/2 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State) | 10.9 ± NA | 18.1 ± NA | 30.4 ± NA | 21.0 ± 22.8 | 17.2 ± 9.70 | 17.4 ± 9.64 | 13.1 ± 6.01 |
Cmin was defined as the minimum observed plasma concentration over the dose interval.
| ng/mL | Part 1: Intermittent Pemigatinib 1 mg QD | Part 1: Intermittent Pemigatinib 2 mg QD | Part 1: Intermittent Pemigatinib 4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Cmin After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State) | 3.24 ± NA | 7.87 ± NA | 23.9 ± NA | 30.0 ± 15.1 | 49.9 ± 49.6 | 71.7 ± 56.7 | 104 ± 93.3 |
AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.
| hr*ng/mL | Part 1: Intermittent Pemigatinib 1 mg QD | Part 1: Intermittent Pemigatinib 2 mg QD | Part 1: Intermittent Pemigatinib 4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State) | 208 ± NA | 322 ± NA | 1380 ± NA | 1080 ± 301 | 2180 ± 1630 | 3010 ± 1890 | 4350 ± 1480 |
CL/F was defined as the apparent oral dose clearance.
| Liters per hr (L/hr) | Part 1: Intermittent Pemigatinib 1 mg QD | Part 1: Intermittent Pemigatinib 2 mg QD | Part 1: Intermittent Pemigatinib 4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: CL/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State) | 9.86 ± NA | 12.8 ± NA | 5.93 ± NA | 12.0 ± 3.14 | 15.7 ± 17.7 | 11.9 ± 5.72 | 10.3 ± 3.01 |
Vz/F was defined as the apparent volume of distribution.
| Liters | Part 1: Intermittent Pemigatinib 1 mg QD | Part 1: Intermittent Pemigatinib 2 mg QD | Part 1: Intermittent Pemigatinib 4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Vz/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State) | 156 ± NA | 334 ± NA | 260 ± NA | 301 ± 241 | 246 ± 76.1 | 274 ± 165 | 180 ± 49.1 |
The accumulation ratio was defined as the ratio of the accumulation of a drug under steady-state conditions as compared to a single dose.
| ratio | Part 1: Intermittent Pemigatinib 1 mg QD | Part 1: Intermittent Pemigatinib 2 mg QD | Part 1: Intermittent Pemigatinib 4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Accumulation Ratio After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State) | 1.09 ± NA | 1.64 ± NA | 1.36 ± NA | 1.67 ± 0.264 | 1.71 ± 0.534 | 1.69 ± 0.538 | 1.76 ± 0.476 |
Cmax was defined as the maximum observed plasma concentration.
| ng/mL | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed |
|---|---|---|
| Parts 1 and 2: Cmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States | 215 ± 86.5 | 179 ± 82.8 |
tmax was defined as the time to the maximum observed plasma concentration.
| hr | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed |
|---|---|---|
| Parts 1 and 2: Tmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States | 1.58 (0.500 to 5.78) | 4.02 (1.00 to 7.58) |
t1/2 was defined as the apparent plasma terminal phase disposition half-life.
| hr | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed |
|---|---|---|
| Parts 1 and 2: t1/2 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States | 19.2 ± 10.5 | 23.8 ± 17.5 |
Cmin was defined as the minimum observed plasma concentration over the dose interval.
| ng/mL | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed |
|---|---|---|
| Parts 1 and 2: Cmin Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States | 61.1 ± 33.5 | 65.7 ± 34.7 |
AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.
| hr*ng/mL | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed |
|---|---|---|
| Parts 1 and 2: AUC0-24 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States | 2580 ± 999 | 2910 ± 1310 |
CL/F was defined as the apparent oral dose clearance.
| L/hr | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed |
|---|---|---|
| Parts 1 and 2: CL/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States | 12.4 ± 4.94 | 11.3 ± 4.87 |
Vz/F was defined as the apparent volume of distribution.
| Liters | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted | Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed |
|---|---|---|
| Parts 1 and 2: Vz/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States | 307 ± 139 | 364 ± 262 |
Cmax was defined as the maximum observed plasma concentration.
| ng/mL | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg |
|---|---|---|---|---|---|
| Part 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1 | 137 ± 65.7 | 199 ± 99.6 | 234 ± 84.1 | 214 ± 98.2 | 259 ± 55.4 |
tmax was defined as the time to the maximum observed plasma concentration.
| hr | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg |
|---|---|---|---|---|---|
| Part 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1 | 1.98 (1.00 to 4.00) | 1.05 (0.500 to 23.4) | 2.00 (0.500 to 22.6) | 1.00 (0.500 to 3.98) | 0.783 (0.500 to 18.6) |
AUClast was defined as the area under the plasma or serum concentration-time curve from the time of dosing to the last measurable concentration.
| hr*ng/mL | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg |
|---|---|---|---|---|---|
| Part 3: AUClast of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1 | 1480 ± 587 | 1880 ± 821 | 2890 ± 1010 | 1890 ± 491 | 2040 ± 513 |
AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.
| hr*ng/mL | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg |
|---|---|---|---|---|---|
| Part 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1 | 1550 ± 552 | 1910 ± 838 | 2920 ± 1070 | 1890 ± 471 | 1890 ± 269 |
Cmax was defined as the maximum observed plasma concentration.
| ng/mL | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg |
|---|---|---|---|---|---|
| Part 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State) | 166 ± 52.1 | 255 ± 119 | 214 ± 203 | 231 ± 99.4 | 404 ± 41.7 |
tmax was defined as the time to the maximum observed plasma concentration.
| hr | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg |
|---|---|---|---|---|---|
| Part 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State) | 5.78 (1.25 to 6.08) | 1.08 (0.500 to 7.98) | 1.50 (0.950 to 4.00) | 1.90 (0.500 to 2.08) | 0.583 (0.500 to 1.07) |
t1/2 was defined as the apparent plasma terminal phase disposition half-life.
| hr | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg |
|---|---|---|---|---|---|
| Part 3: t1/2 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State) | 15.3 ± 0.207 | 17.0 ± 6.90 | 10.6 ± 3.29 | 14.7 ± 6.43 | 15.3 ± 2.64 |
Cmin was defined as the minimum observed plasma concentration over the dose interval.
| ng/mL | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg |
|---|---|---|---|---|---|
| Part 3: Cmin of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State) | 58.0 ± 31.6 | 56.6 ± 31.3 | 48.5 ± 57.8 | 63.1 ± 32.4 | 64.2 ± 25.8 |
AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.
| hr*ng/mL | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg |
|---|---|---|---|---|---|
| Part 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State) | 2400 ± 628 | 2400 ± 967 | 1650 ± 1060 | 2910 ± 1390 | 3440 ± 672 |
CL/F was defined as the apparent oral dose clearance.
| L/hr | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg |
|---|---|---|---|---|---|
| Part 3: CL/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State) | 8.03 ± 1.89 | 13.4 ± 5.46 | 24.5 ± 17.7 | 12.7 ± 9.03 | 8.26 ± 1.39 |
Vz/F was defined as the apparent volume of distribution.
| Liters | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg |
|---|---|---|---|---|---|
| Part 3: Vz/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State) | 177 ± 39.8 | 303 ± 136 | 376 ± 261 | 227 ± 82.2 | 182 ± 43.2 |
The accumulation ratio was defined as the ratio of the accumulation of a drug under steady-state conditions as compared to a single dose.
| ratio | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg |
|---|---|---|---|---|---|
| Part 3: Accumulation Ratio of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State) | 1.65 ± 0.501 | 1.53 ± 0.381 | 0.604 ± 0.265 | 1.52 ± 0.772 | 1.90 ± 0.432 |
Collected over up to 869 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Intermittent Pemigatinib 1/2/4 mg QD | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1: Intermittent Pemigatinib 6 mg QD | 2/4 (50%) | 0/4 (0%) | 3/4 (75%) |
| Parts 1 and 2: Intermittent Pemigatinib 9 mg QD | 6/7 (85.7%) | 3/7 (42.9%) | 7/7 (100%) |
| Parts 1 and 2: Intermittent Pemigatinib 13.5 mg QD | 37/50 (74%) | 21/50 (42%) | 50/50 (100%) |
| Part 1: Intermittent Pemigatinib 20 mg QD | 6/6 (100%) | 3/6 (50%) | 6/6 (100%) |
| Parts 1 and 2: Continuous Pemigatinib 9 mg QD | 10/14 (71.4%) | 6/14 (42.9%) | 14/14 (100%) |
| Parts 1 and 2: Continuous Pemigatinib 13.5 mg QD | 21/30 (70%) | 14/30 (46.7%) | 30/30 (100%) |
| Parts 1 and 2: Continuous Pemigatinib 20 mg QD | 10/15 (66.7%) | 7/15 (46.7%) | 15/15 (100%) |
| Part 1: Continuous Pemigatinib 7.5 mg BID | 4/4 (100%) | 2/4 (50%) | 4/4 (100%) |
| Part 1: Continuous Pemigatinib 10 mg BID | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 3: Gem/Cis/Intermittent Pemigatinib 9 mg | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | 7/7 (100%) | 3/7 (42.9%) | 7/7 (100%) |
| Part 3: Tras/Intermittent Pemigatinib 13.5 mg | 5/6 (83.3%) | 0/6 (0%) | 6/6 (100%) |
| Part 3: Doc/Intermittent Pemigatinib 13.5 mg | 5/7 (71.4%) | 6/7 (85.7%) | 7/7 (100%) |
| Part 3: Pem/Intermittent Pemigatinib 9 mg | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 3: Pem/Intermittent Pemigatinib 13.5 mg | 9/14 (64.3%) | 7/14 (50%) | 14/14 (100%) |
| Part 3: Pem/Continuous Pemigatinib 13.5 mg | 6/9 (66.7%) | 3/9 (33.3%) | 9/9 (100%) |
| Part 3: Ref/Continuous Pemigatinib 9 mg | 6/7 (85.7%) | 4/7 (57.1%) | 7/7 (100%) |
| Part 3: Ref/Continuous Pemigatinib 13.5 mg | 3/9 (33.3%) | 5/9 (55.6%) | 9/9 (100%) |
| Part 3: Ref/Continuous Pemigatinib 20 mg | 0/2 (0%) | 2/2 (100%) | 2/2 (100%) |
| Event | Part 1: Intermittent Pemigatinib 1/2/4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent Pemigatinib 13.5 mg QD | Part 1: Intermittent Pemigatinib 20 mg QD | Parts 1 and 2: Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Continuous Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 7.5 mg BID | Part 1: Continuous Pemigatinib 10 mg BID | Part 3: Gem/Cis/Intermittent Pemigatinib 9 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 9 mg | Part 3: Ref/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 20 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 0/3 | 0/4 | 0/7 | 0/50 | 0/6 | 1/14 | 3/30 | 0/15 | 0/4 | 0/3 | 0/1 | 1/7 | 0/6 | 1/7 | 0/3 | 0/14 | 0/9 | 1/7 | 0/9 | 2/2 |
| ConstipationGastrointestinal disorders | 0/3 | 0/4 | 1/7 | 0/50 | 0/6 | 0/14 | 0/30 | 1/15 | 0/4 | 0/3 | 1/1 | 0/7 | 0/6 | 0/7 | 0/3 | 0/14 | 0/9 | 0/7 | 0/9 | 0/2 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 0/4 | 0/7 | 0/50 | 0/6 | 0/14 | 0/30 | 0/15 | 0/4 | 0/3 | 1/1 | 0/7 | 0/6 | 0/7 | 0/3 | 0/14 | 0/9 | 0/7 | 0/9 | 0/2 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/4 | 0/7 | 1/50 | 0/6 | 0/14 | 0/30 | 1/15 | 0/4 | 0/3 | 0/1 | 0/7 | 0/6 | 1/7 | 0/3 | 1/14 | 0/9 | 0/7 | 1/9 | 1/2 |
| FatigueGeneral disorders | 0/3 | 0/4 | 0/7 | 1/50 | 0/6 | 0/14 | 3/30 | 1/15 | 0/4 | 0/3 | 0/1 | 0/7 | 0/6 | 1/7 | 0/3 | 0/14 | 0/9 | 1/7 | 0/9 | 1/2 |
| PneumoniaInfections and infestations | 0/3 | 0/4 | 2/7 | 2/50 | 1/6 | 1/14 | 1/30 | 1/15 | 2/4 | 0/3 | 0/1 | 0/7 | 0/6 | 0/7 | 0/3 | 0/14 | 1/9 | 0/7 | 1/9 | 0/2 |
| Completed suicidePsychiatric disorders | 0/3 | 0/4 | 0/7 | 0/50 | 0/6 | 0/14 | 0/30 | 0/15 | 0/4 | 0/3 | 0/1 | 0/7 | 0/6 | 0/7 | 1/3 | 0/14 | 0/9 | 0/7 | 0/9 | 0/2 |
| Depressed level of consciousnessNervous system disorders | 1/3 | 0/4 | 0/7 | 0/50 | 0/6 | 0/14 | 0/30 | 0/15 | 0/4 | 0/3 | 0/1 | 0/7 | 0/6 | 0/7 | 0/3 | 0/14 | 0/9 | 0/7 | 0/9 | 0/2 |
| Disease progressionGeneral disorders | 1/3 | 0/4 | 0/7 | 1/50 | 0/6 | 0/14 | 1/30 | 1/15 | 0/4 | 1/3 | 0/1 | 1/7 | 0/6 | 0/7 | 0/3 | 0/14 | 0/9 | 0/7 | 1/9 | 0/2 |
| HypertensionVascular disorders | 0/3 | 0/4 | 0/7 | 0/50 | 0/6 | 0/14 | 0/30 | 0/15 | 0/4 | 1/3 | 0/1 | 0/7 | 0/6 | 0/7 | 0/3 | 1/14 | 0/9 | 0/7 | 0/9 | 0/2 |
| Event | Part 1: Intermittent Pemigatinib 1/2/4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Parts 1 and 2: Intermittent Pemigatinib 9 mg QD | Parts 1 and 2: Intermittent Pemigatinib 13.5 mg QD | Part 1: Intermittent Pemigatinib 20 mg QD | Parts 1 and 2: Continuous Pemigatinib 9 mg QD | Parts 1 and 2: Continuous Pemigatinib 13.5 mg QD | Parts 1 and 2: Continuous Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 7.5 mg BID | Part 1: Continuous Pemigatinib 10 mg BID | Part 3: Gem/Cis/Intermittent Pemigatinib 9 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 9 mg | Part 3: Ref/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 20 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/3 | 0/4 | 1/7 | 10/50 | 1/6 | 2/14 | 6/30 | 2/15 | 0/4 | 0/3 | 1/1 | 1/7 | 0/6 | 1/7 | 0/3 | 2/14 | 2/9 | 0/7 | 1/9 | 0/2 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/3 | 0/4 | 3/7 | 15/50 | 1/6 | 6/14 | 11/30 | 5/15 | 1/4 | 2/3 | 0/1 | 1/7 | 5/6 | 3/7 | 0/3 | 6/14 | 5/9 | 1/7 | 3/9 | 2/2 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/4 | 1/7 | 10/50 | 2/6 | 6/14 | 6/30 | 4/15 | 2/4 | 1/3 | 1/1 | 7/7 | 2/6 | 3/7 | 1/3 | 7/14 | 3/9 | 2/7 | 0/9 | 1/2 |
| Blood creatinine increasedInvestigations | 0/3 | 0/4 | 1/7 | 2/50 | 0/6 | 0/14 | 11/30 | 4/15 | 1/4 | 0/3 | 1/1 | 4/7 | 1/6 | 1/7 | 1/3 | 4/14 | 1/9 | 1/7 | 2/9 | 2/2 |
| DehydrationMetabolism and nutrition disorders | 1/3 | 1/4 | 0/7 | 6/50 | 1/6 | 1/14 | 4/30 | 4/15 | 4/4 | 1/3 | 1/1 | 1/7 | 0/6 | 4/7 | 1/3 | 2/14 | 1/9 | 3/7 | 3/9 | 1/2 |
| Dry mouthGastrointestinal disorders | 0/3 | 1/4 | 3/7 | 17/50 | 2/6 | 5/14 | 13/30 | 8/15 | 2/4 | 3/3 | 1/1 | 2/7 | 4/6 | 1/7 | 0/3 | 4/14 | 5/9 | 4/7 | 3/9 | 2/2 |
| DysgeusiaNervous system disorders | 1/3 | 0/4 | 1/7 | 5/50 | 1/6 | 2/14 | 9/30 | 4/15 | 4/4 | 2/3 | 0/1 | 2/7 | 0/6 | 3/7 | 0/3 | 2/14 | 1/9 | 1/7 | 2/9 | 0/2 |
| HyperphosphataemiaMetabolism and nutrition disorders | 0/3 | 1/4 | 4/7 | 39/50 | 4/6 | 8/14 | 28/30 | 13/15 | 4/4 | 3/3 | 1/1 | 3/7 | 5/6 | 6/7 | 3/3 | 11/14 | 5/9 | 4/7 | 5/9 | 2/2 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 0/3 | 0/4 | 0/7 | 3/50 | 0/6 | 0/14 | 2/30 | 1/15 | 0/4 | 0/3 | 1/1 | 0/7 | 1/6 | 1/7 | 1/3 | 2/14 | 0/9 | 0/7 | 0/9 | 0/2 |
| HypokalaemiaMetabolism and nutrition disorders | 1/3 | 1/4 | 2/7 | 3/50 | 0/6 | 2/14 | 1/30 | 2/15 | 1/4 | 1/3 | 1/1 | 2/7 | 0/6 | 0/7 | 0/3 | 3/14 | 0/9 | 2/7 | 1/9 | 0/2 |
| Age, Continuous(years) | Part 1: Intermittent Pemigatinib 1/2/4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Part 1: Intermittent Pemigatinib 9 mg QD | Part 1: Intermittent Pemigatinib 13.5 mg QD | Part 1: Intermittent Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 9 mg QD | Part 1: Continuous Pemigatinib 13.5 mg QD | Part 1: Continuous Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 7.5 mg BID | Part 1: Continuous Pemigatinib 10 mg BID | Part 2: Intermittent Pemigatinib 9 mg QD | Part 2: Intermittent Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 9 mg QD | Part 2: Continuous Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 20 mg QD | Part 3: Gem/Cis/Intermittent Pemigatinib 9 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 9 mg | Part 3: Ref/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 20 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 60.7 ± 11.24 | 45.5 ± 17.31 | 56.3 ± 4.93 | 59.0 ± 14.79 | 56.2 ± 11.89 | 57.9 ± 15.70 | 61.2 ± 16.88 | 56.3 ± 15.19 | 66.8 ± 4.57 | 68.7 ± 15.89 | 50.3 ± 12.39 | 57.7 ± 11.81 | 63.8 ± 10.69 | 57.4 ± 13.78 | 58.3 ± 8.80 | 61.0 ± NA | 54.1 ± 10.43 | 47.8 ± 14.44 | 62.4 ± 9.16 | 55.0 ± 15.72 | 64.7 ± 10.50 | 61.8 ± 10.89 | 63.4 ± 11.43 | 66.9 ± 8.80 | 68.0 ± 7.07 | 59.0 ± 12.61 |
| Sex: Female, Male(Participants) | Part 1: Intermittent Pemigatinib 1/2/4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Part 1: Intermittent Pemigatinib 9 mg QD | Part 1: Intermittent Pemigatinib 13.5 mg QD | Part 1: Intermittent Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 9 mg QD | Part 1: Continuous Pemigatinib 13.5 mg QD | Part 1: Continuous Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 7.5 mg BID | Part 1: Continuous Pemigatinib 10 mg BID | Part 2: Intermittent Pemigatinib 9 mg QD | Part 2: Intermittent Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 9 mg QD | Part 2: Continuous Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 20 mg QD | Part 3: Gem/Cis/Intermittent Pemigatinib 9 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 9 mg | Part 3: Ref/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 20 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 2 | 3 | 3 | 6 | 5 | 6 | 0 | 2 | 3 | 27 | 5 | 10 | 5 | 0 | 3 | 4 | 3 | 1 | 5 | 3 | 7 | 5 | 1 | 113 |
| Male | 1 | 2 | 1 | 3 | 3 | 3 | 5 | 3 | 4 | 1 | 1 | 17 | 0 | 10 | 1 | 1 | 4 | 2 | 4 | 2 | 9 | 6 | 0 | 4 | 1 | 88 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Intermittent Pemigatinib 1/2/4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Part 1: Intermittent Pemigatinib 9 mg QD | Part 1: Intermittent Pemigatinib 13.5 mg QD | Part 1: Intermittent Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 9 mg QD | Part 1: Continuous Pemigatinib 13.5 mg QD | Part 1: Continuous Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 7.5 mg BID | Part 1: Continuous Pemigatinib 10 mg BID | Part 2: Intermittent Pemigatinib 9 mg QD | Part 2: Intermittent Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 9 mg QD | Part 2: Continuous Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 20 mg QD | Part 3: Gem/Cis/Intermittent Pemigatinib 9 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 9 mg | Part 3: Ref/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 20 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 4 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 15 |
| Not Hispanic or Latino | 2 | 3 | 3 | 6 | 4 | 8 | 9 | 9 | 4 | 3 | 3 | 39 | 5 | 16 | 6 | 1 | 7 | 6 | 7 | 3 | 13 | 8 | 7 | 9 | 1 | 182 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Race/Ethnicity, Customized(Participants) | Part 1: Intermittent Pemigatinib 1/2/4 mg QD | Part 1: Intermittent Pemigatinib 6 mg QD | Part 1: Intermittent Pemigatinib 9 mg QD | Part 1: Intermittent Pemigatinib 13.5 mg QD | Part 1: Intermittent Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 9 mg QD | Part 1: Continuous Pemigatinib 13.5 mg QD | Part 1: Continuous Pemigatinib 20 mg QD | Part 1: Continuous Pemigatinib 7.5 mg BID | Part 1: Continuous Pemigatinib 10 mg BID | Part 2: Intermittent Pemigatinib 9 mg QD | Part 2: Intermittent Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 9 mg QD | Part 2: Continuous Pemigatinib 13.5 mg QD | Part 2: Continuous Pemigatinib 20 mg QD | Part 3: Gem/Cis/Intermittent Pemigatinib 9 mg | Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg | Part 3: Tras/Intermittent Pemigatinib 13.5 mg | Part 3: Doc/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Intermittent Pemigatinib 9 mg | Part 3: Pem/Intermittent Pemigatinib 13.5 mg | Part 3: Pem/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 9 mg | Part 3: Ref/Continuous Pemigatinib 13.5 mg | Part 3: Ref/Continuous Pemigatinib 20 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White/Caucasian | 3 | 4 | 2 | 6 | 5 | 8 | 10 | 8 | 4 | 3 | 3 | 37 | 5 | 18 | 6 | 1 | 5 | 6 | 6 | 2 | 10 | 9 | 7 | 9 | 1 | 178 |
| Black/African-American | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 1 | 15 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| American-Indian/Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian/Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Captured as Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2015 to primary completion in Dec 2021, 81 months.
Results were first posted in Jan 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemigatinib